20mins delayed


1 Year Return

Exopharm Limited Chart

Share price
Market Cap $17.94 million
Today's Movement
Prev. Close
Day Range -
Historical Stats
52w Range -
4w Avg Volume
4w Avg Turnover

EX1 Statistics

24 January

1,566 / 2,295

ASX Size Rank

1yr Return

vs Sector (1yr)


vs ASX 200 (1yr)


$17.94 million

Market Cap

Share Issue

59.81 million

All Ords (%)


Short Sold


Current Fundamentals

24 January


PE Ratio

EPS ($)


Earnings Yield


NTA ($)



Dividend Yield

DPS ($)


Gross Div. Yield


Gross DPS ($)


Company Overview

Exopharm Limited (EX1) is an Australian biopharmaceutical company that deals in developing regenerative medicine, primarily being the development and de-risking of exosome technologies, particularly the LEAP manufacturing process and development of the PlexarisTM and ExomereTM products.

Exopharm Limited Logo

Corporate Details

Head Office: Melbourne
Managing Director: Ian Dixon
GICS Sub-Industry: Biotechnology
Date Listed: 18 Dec 2018
Registry: Automic
Similar Companies: CSL / SRX / MSB / CUV / VLA

Upcoming Calendar

Dividend History

Ex-Date Amount Franking Type Payable
No dividends paid in the last 5 years

See Upcoming Dividends for all ASX companies.


Date Heading Pages File Size Time

Broker Consensus

The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.

EX1 is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.

Directors & Management

About the Data

Name Title Since Bio
Mr David Rodney Parker Company Secretary, Non-Executive Director Jun 2018
Dr Ian Edward Dixon Company Founder, Technology Co-Founder, Managing Director May 2013
Mr Jason Mark Watson Non-Executive Chairman, Non-Executive Director Aug 2018

Director Transactions

About the Data

EX1 directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
13/09/19 Jason Watson Issued 100,000 $0.370 $37,000 Placement.
19/08/19 David Parker Buy +20,000 $0.370 $7,400 Participation in share purchase plan.
19/08/19 Ian Dixon Buy +40,000 $0.370 $14,800 Participation in share purchase plan.
19/08/19 Jason Watson Buy +40,000 $0.370 $14,800 Participation in share purchase plan.

Shareholder Distribution

About the Data

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over Total Shareholders
No. of Shareholders 21 80 125 549 166 941

Top 20 Shareholders

About the Data

Name Shares Capital
Altnia Holdings Pty Ltd (Dixon Family A/C) 27,975,294 29.33%
Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon (Mcmahon Super Fund A/C) 2,310,000 2.42%
Oldview Enterprises Pty Ltd (The Priestley A/C) 1,476,963 1.55%
Anthony John Locantro 1,330,000 1.39%
Carda Pty Ltd (Carda Super Fund A/C) 1,220,000 1.28%
Phytose Corporation Pty Limited (Boundaryone Super A/C) 1,176,471 1.23%
Pabasa Pty Ltd (Kehoe Family Super Fund A/C) 1,000,000 1.05%
Mrs Anna Felicia Belton 978,334 1.03%
Acns Capital Markets Pty Ltd 810,000 0.85%
Drp 2006 Super Pty Ltd (Drp (2006) Super Fund A/C) 760,000 0.80%
Basapa Pty Ltd (Kehoe Family A/C) 750,000 0.79%
Kohen Enterprises Pty Ltd 750,000 0.79%
Lonhro (Wa) Pty Ltd (Lonhro A/C) 736,667 0.74%
Saintly Company Pty Ltd (Walker Investment A/C) 670,000 0.70%
Mr Andrew Stewart Coles & Ms Alexandra Constance Manook (Coles Family Super A/C) 615,000 0.64%
Gregor Lichtfuss 588,235 0.62%
Mr Anthony De Nicola & Mrs Tanya Louise De Nicola (De Nicola Family S/F A/C) 575,000 0.60%
Jeccs Pty Ltd (Brown Family No1 A/C) 547,000 0.57%
Labonne Enterprises Pty Ltd (Mcintyre Family A/C) 500,000 0.52%
Ringsford Pty Ltd (Dg & Gl Walker S/F A/C) 500,000 0.52%
All other shareholders 52.58 %

The Top 20 Shareholders of EX1 hold 47.42% of shares on issue.

EX1 Share Price History

Date Close Change % Change Open High Low Volume Turnover

EX1 Historical Data

Download up to 20 years of share price history.

Year Closing Price (30 June) Last Trade

Offical data as published by ASX. See more Data Downloads.

Company Details

Principal Activity: Developing regenerative medicine, primarily being the development and de-risking of exosome technologies, particularly the LEAP manufacturing process and development of the Plexaris and Exomere products.

Incorporated: --

Level 17, 31 Queen St
Melbourne VIC 3000

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.